JWD Your personal alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Wildlife Diseases, 40(3), 2004, pp. 533-537
© Wildlife Disease Association  2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, B. F.
Right arrow Articles by Warren, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, B. F.
Right arrow Articles by Warren, R. J.

EFFECTIVENESS OF ANTAGONISTS FOR TILETAMINE-ZOLAZEPAM/XYLAZINE IMMOBILIZATION IN FEMALE WHITE-TAILED DEER

Brad F. Miller1,4, Lisa I. Muller1,5, Tom Doherty2, David A. Osborn3, Karl V. Miller3 and Robert J. Warren3

1 Department of Forestry, Wildlife and Fisheries, University of Tennessee, 274 Ellington Hall, Knoxville, Tennessee 37996, USA
2 Department of Large Animal Medicine, University of Tennessee, Veterinary Teaching Hospital, Knoxville, Tennessee 37996, USA
3 Warnell School of Forest Resources, University of Georgia, Athens, Georgia 30602, USA

5 Corresponding author (email: lmuller{at}utk.edu)

A combination of tiletamine-zolazepam/xylazine (TZ/X) is effective in the chemical immobilization of white-tailed deer (Odocoileus virginianus); however, the lengthy duration of immobilization may limit its usefulness. From October to November 2002, 21 captive female deer were assigned randomly to an {alpha}2 antagonist treatment to reverse xylazine-induced sedation (seven does per group). All deer were given 220 mg of TZ (4.5±0.4 mg/kg) and 110 mg of X (2.2±0.2 mg/kg) intramuscularly (IM). Antagonist treatments were either 200 mg of tolazoline (4.0±0.4 mg/kg), 11 mg of atipamezole (0.23±0.02 mg/kg), or 15 mg of yohimbine (0.30±0.02 mg/kg) injected, half intravenously and half subcutaneously, 45 min after the IM TZ/X injection. In addition, 10 other deer (five per group) were immobilized as before and then given tolazoline (200 mg) after 45 min, with either a carrier (dimethyl sulfoxide [DMSO]) or carrier (DMSO) plus flumazenil (5 mg) to reverse the zolazepam portion of TZ. Mean times from antagonist injection until a deer raised its head were different for {alpha}2 antagonist treatments (P=0.02). Times were longer for yohimbine (62.3±42.7 min) than for either atipamezole (24.3±17.1 min) or tolazoline (21.3±14.3 min). Mean times from antagonist injection until standing were not different (P=0.15) among yohimbine (112.0±56.4 min), atipamezole (89.7±62.8 min), or tolazoline (52.6±37.2 min). A sedation score based on behavioral criteria was assigned to each deer every 30 min for 5 hr. On the basis of sedation scores, tolazoline resulted in a faster and more complete reversal of immobilization. Flumazenil treatment did not affect recovery.

  Key words:  Antagonist, atipamezole, flumazenil, immobilization, Odocoileus virginianus, Telazol®, tiletamine, tolazoline, white-tailed deer, xylazine, yohimbine, zolazepam.

4 Present address: Warnell School of Forest Resources, University of Georgia, Athens, Georgia 30602, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Wildlife Disease Association.